Research ExplorerPublicationsFurther pharmacological and genetic evidence for the efficac...

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

Standard

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. / Van de Veire, Sara; Stalmans, Ingeborg; Heindryckx, Femke; Oura, Hajimu; Tijeras-Raballand, Annemilaï; Schmidt, Thomas; Loges, Sonja; Albrecht, Imke; Jonckx, Bart; Vinckier, Stefan; Van Steenkiste, Christophe; Tugues, Sònia; Rolny, Charlotte; De Mol, Maria; Dettori, Daniela; Hainaud, Patricia; Coenegrachts, Lieve; Contreres, Jean-Olivier; Van Bergen, Tine; Cuervo, Henar; Xiao, Wei-Hong; Le Henaff, Carole; Buysschaert, Ian; Kharabi Masouleh, Behzad; Geerts, Anja; Schomber, Tibor; Bonnin, Philippe; Lambert, Vincent; Haustraete, Jurgen; Zacchigna, Serena; Rakic, Jean-Marie; Jiménez, Wladimiro; Noël, Agnes; Giacca, Mauro; Colle, Isabelle; Foidart, Jean-Michel; Tobelem, Gerard; Morales-Ruiz, Manuel; Vilar, José; Maxwell, Patrick; Vinores, Stanley A; Carmeliet, Geert; Dewerchin, Mieke; Claesson-Welsh, Lena; Dupuy, Evelyne; Van Vlierberghe, Hans; Christofori, Gerhard; Mazzone, Massimiliano; Detmar, Michael; Collen, Désiré; Carmeliet, Peter.

In: CELL, Vol. 141, No. 1, 02.04.2010, p. 178-90.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Van de Veire, S, Stalmans, I, Heindryckx, F, Oura, H, Tijeras-Raballand, A, Schmidt, T, Loges, S, Albrecht, I, Jonckx, B, Vinckier, S, Van Steenkiste, C, Tugues, S, Rolny, C, De Mol, M, Dettori, D, Hainaud, P, Coenegrachts, L, Contreres, J-O, Van Bergen, T, Cuervo, H, Xiao, W-H, Le Henaff, C, Buysschaert, I, Kharabi Masouleh, B, Geerts, A, Schomber, T, Bonnin, P, Lambert, V, Haustraete, J, Zacchigna, S, Rakic, J-M, Jiménez, W, Noël, A, Giacca, M, Colle, I, Foidart, J-M, Tobelem, G, Morales-Ruiz, M, Vilar, J, Maxwell, P, Vinores, SA, Carmeliet, G, Dewerchin, M, Claesson-Welsh, L, Dupuy, E, Van Vlierberghe, H, Christofori, G, Mazzone, M, Detmar, M, Collen, D & Carmeliet, P 2010, 'Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease', CELL, vol. 141, no. 1, pp. 178-90. https://doi.org/10.1016/j.cell.2010.02.039

APA

Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., Van Steenkiste, C., Tugues, S., Rolny, C., De Mol, M., Dettori, D., Hainaud, P., Coenegrachts, L., Contreres, J-O., Van Bergen, T., ... Carmeliet, P. (2010). Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. CELL, 141(1), 178-90. https://doi.org/10.1016/j.cell.2010.02.039

Vancouver

Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. CELL. 2010 Apr 2;141(1):178-90. https://doi.org/10.1016/j.cell.2010.02.039

Bibtex

@article{e081b518357149a9b2a9d07e7eb4e536,
title = "Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease",
abstract = "Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.",
keywords = "Angiogenesis Inhibitors, Animals, Antibodies, Monoclonal, Carcinoma, Hepatocellular, Choroid, Disease Models, Animal, Eye Diseases, Humans, Liver Neoplasms, Experimental, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neovascularization, Physiologic, Papilloma, Placenta Growth Factor, Pregnancy Proteins, Skin Neoplasms, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't",
author = "{Van de Veire}, Sara and Ingeborg Stalmans and Femke Heindryckx and Hajimu Oura and Annemila{\"i} Tijeras-Raballand and Thomas Schmidt and Sonja Loges and Imke Albrecht and Bart Jonckx and Stefan Vinckier and {Van Steenkiste}, Christophe and S{\`o}nia Tugues and Charlotte Rolny and {De Mol}, Maria and Daniela Dettori and Patricia Hainaud and Lieve Coenegrachts and Jean-Olivier Contreres and {Van Bergen}, Tine and Henar Cuervo and Wei-Hong Xiao and {Le Henaff}, Carole and Ian Buysschaert and {Kharabi Masouleh}, Behzad and Anja Geerts and Tibor Schomber and Philippe Bonnin and Vincent Lambert and Jurgen Haustraete and Serena Zacchigna and Jean-Marie Rakic and Wladimiro Jim{\'e}nez and Agnes No{\"e}l and Mauro Giacca and Isabelle Colle and Jean-Michel Foidart and Gerard Tobelem and Manuel Morales-Ruiz and Jos{\'e} Vilar and Patrick Maxwell and Vinores, {Stanley A} and Geert Carmeliet and Mieke Dewerchin and Lena Claesson-Welsh and Evelyne Dupuy and {Van Vlierberghe}, Hans and Gerhard Christofori and Massimiliano Mazzone and Michael Detmar and D{\'e}sir{\'e} Collen and Peter Carmeliet",
note = "Copyright 2010 Elsevier Inc. All rights reserved.",
year = "2010",
month = apr,
day = "2",
doi = "10.1016/j.cell.2010.02.039",
language = "English",
volume = "141",
pages = "178--90",
journal = "CELL",
issn = "0092-8674",
publisher = "Cell Press",
number = "1",

}

RIS

TY - JOUR

T1 - Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

AU - Van de Veire, Sara

AU - Stalmans, Ingeborg

AU - Heindryckx, Femke

AU - Oura, Hajimu

AU - Tijeras-Raballand, Annemilaï

AU - Schmidt, Thomas

AU - Loges, Sonja

AU - Albrecht, Imke

AU - Jonckx, Bart

AU - Vinckier, Stefan

AU - Van Steenkiste, Christophe

AU - Tugues, Sònia

AU - Rolny, Charlotte

AU - De Mol, Maria

AU - Dettori, Daniela

AU - Hainaud, Patricia

AU - Coenegrachts, Lieve

AU - Contreres, Jean-Olivier

AU - Van Bergen, Tine

AU - Cuervo, Henar

AU - Xiao, Wei-Hong

AU - Le Henaff, Carole

AU - Buysschaert, Ian

AU - Kharabi Masouleh, Behzad

AU - Geerts, Anja

AU - Schomber, Tibor

AU - Bonnin, Philippe

AU - Lambert, Vincent

AU - Haustraete, Jurgen

AU - Zacchigna, Serena

AU - Rakic, Jean-Marie

AU - Jiménez, Wladimiro

AU - Noël, Agnes

AU - Giacca, Mauro

AU - Colle, Isabelle

AU - Foidart, Jean-Michel

AU - Tobelem, Gerard

AU - Morales-Ruiz, Manuel

AU - Vilar, José

AU - Maxwell, Patrick

AU - Vinores, Stanley A

AU - Carmeliet, Geert

AU - Dewerchin, Mieke

AU - Claesson-Welsh, Lena

AU - Dupuy, Evelyne

AU - Van Vlierberghe, Hans

AU - Christofori, Gerhard

AU - Mazzone, Massimiliano

AU - Detmar, Michael

AU - Collen, Désiré

AU - Carmeliet, Peter

N1 - Copyright 2010 Elsevier Inc. All rights reserved.

PY - 2010/4/2

Y1 - 2010/4/2

N2 - Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

AB - Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

KW - Angiogenesis Inhibitors

KW - Animals

KW - Antibodies, Monoclonal

KW - Carcinoma, Hepatocellular

KW - Choroid

KW - Disease Models, Animal

KW - Eye Diseases

KW - Humans

KW - Liver Neoplasms, Experimental

KW - Mice

KW - Mice, Inbred BALB C

KW - Mice, Inbred C57BL

KW - Mice, Transgenic

KW - Neovascularization, Physiologic

KW - Papilloma

KW - Placenta Growth Factor

KW - Pregnancy Proteins

KW - Skin Neoplasms

KW - Journal Article

KW - Research Support, N.I.H., Extramural

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.cell.2010.02.039

DO - 10.1016/j.cell.2010.02.039

M3 - SCORING: Journal article

C2 - 20371353

VL - 141

SP - 178

EP - 190

JO - CELL

JF - CELL

SN - 0092-8674

IS - 1

ER -